Carbapenems and febrile neutropenia

摘要

We read with interest the article by Torfoss et al. [1]. They conducted a randomized study where patients with febrile neutrope-nia received benzylpenicillin plus an aminoglycoside versus meropenem. The study was not investigator blinded. End points were essentially defined as a modification of the initial empirical antibiotic regimen. The primary end point evaluated the clinical situation at 72 h after randomization. The secondary end point was the status 5 days after randomization. All-cause fatalities at 30 days after randomization were recorded but not specified as an end point despite being emphasized in the summary.